poisar

Stocks · News reference

HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target

Benzinga Newsdesk

HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Neutral and maintains $1 price target.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TRAW
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Newsdesk

    Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate

    Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 51.52 percent. This is a 45.45 percent decrease over losses of $(0.11) per share from the

    TRAW
  2. SEC EDGAR

    8-K filing — Traws Pharma, Inc. (TRAW)

    Filed: 2026-08-14 AccNo: 0001104659-26-097226 Size: 312 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    TRAW